Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
AstraZeneca
McKesson
Colorcon
Merck

Last Updated: May 20, 2022

Investigational Drug Information for PHA-793887


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug PHA-793887?

PHA-793887 is an investigational drug.

There have been 32 clinical trials for PHA-793887. The most recent clinical trial was a Phase 3 trial, which was initiated on February 4th 2020.

The most common disease conditions in clinical trials are Neoplasms, Leukemia, and Prostatic Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Nerviano Medical Sciences, and Pfizer.

There are four US patents protecting this investigational drug and sixty-six international patents.

Recent Clinical Trials for PHA-793887
TitleSponsorPhase
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type IIPharvaris Netherlands B.V.Phase 2
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary AngioedemaPharvaris Netherlands B.V.Phase 2
Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludPhase 4

See all PHA-793887 clinical trials

Clinical Trial Summary for PHA-793887

Top disease conditions for PHA-793887
Top clinical trial sponsors for PHA-793887

See all PHA-793887 clinical trials

US Patents for PHA-793887

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PHA-793887 See Plans and Pricing Generation of muscle lineage cells and therapeutic uses thereof GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) See Plans and Pricing
PHA-793887 See Plans and Pricing Maturation of hepatocyte-like cells derived from human pluripotent stem cells Takara Bio Europe AB (Gothenburg, SE) See Plans and Pricing
PHA-793887 See Plans and Pricing Quaternary amine compounds and antibody-drug conjugates thereof Genentech, Inc. (South San Francisco, CA) See Plans and Pricing
PHA-793887 See Plans and Pricing Substituted pyrrolo-pyrazole derivatives as kinase inhibitors Pfizer Italia S.r.l. (Rome, IT) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PHA-793887

Drugname Country Document Number Estimated Expiration Related US Patent
PHA-793887 Australia AU2017351638 2036-10-26 See Plans and Pricing
PHA-793887 Canada CA3044691 2036-10-26 See Plans and Pricing
PHA-793887 China CN110730819 2036-10-26 See Plans and Pricing
PHA-793887 European Patent Office EP3532605 2036-10-26 See Plans and Pricing
PHA-793887 World Intellectual Property Organization (WIPO) WO2018076060 2036-10-26 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
AstraZeneca
McKesson
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.